Aligos therapeutics announces the completion of enrollment in the alg-055009 phase 2a herald study for the treatment of mash

Topline data now projected in early q4 2024 rohit loomba, md, mhsc to serve as principal investigator south san francisco, calif., may 21, 2024 (globe newswire) -- aligos therapeutics, inc. (nasdaq: algs, “aligos”), a clinical stage biopharmaceutical company focused on developing novel therapeutics to address unmet medical needs in liver and viral diseases, today announced that it has completed enrollment in the alg-055009 phase 2a herald study for metabolic dysfunction-associated steatohepatitis (mash) with topline safety and efficacy data anticipated in early q4 2024.
ALGS Ratings Summary
ALGS Quant Ranking